Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of erigeron breviscapus and Scutellarin in preparing medication anti tumor

A technology of scutellarin and scutellarin, applied in the field of pharmaceutical use of flavonoids

Inactive Publication Date: 2006-12-06
上海格鲁奥丽生物技术有限公司
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] So far there is no report about the anti-tumor effect of scutellarin and scutellarin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of erigeron breviscapus and Scutellarin in preparing medication anti tumor
  • Application of erigeron breviscapus and Scutellarin in preparing medication anti tumor
  • Application of erigeron breviscapus and Scutellarin in preparing medication anti tumor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1 Experiment of the inhibitory effect of scutellarin and scutellarin on the growth of tumor cells in vitro

[0029] Drugs to be tested: scutellarin and scutellarin (existing commercial products) were dissolved in dimethyl sulfoxide (DMSO), and used in a 1 / 1000 dilution during actual testing.

[0030]Positive control drug: 5-fluorouracil, dissolved in DMSO, diluted 1 / 1000 for actual testing.

[0031] Method and Results:

[0032] The effects of scutellarin and scutellarin on human lung cancer cell line A549, human leukemia cell line HL60, human gastric cancer cell line MKN28, human colorectal cancer cell line HCT116, human liver cancer cell line HepG2, human esophageal cancer The proliferation inhibition of cell line TE-1 and human breast cancer cell line MCF-7 was measured to measure the IC50 concentration, as well as the IC50 concentration of the positive control drug 5-fluorouracil. At the same time, normal human fibroblasts were used as a control.

[0033] ...

Embodiment 2

[0037] Example 2 Animal Experiment of the Inhibitory Effect of Scutellarin on the Growth of Transplanted Tumor Cells in Mice

[0038] About 20 grams of C57 purebred mice 10 as a group, divided into a control group, a group of high and low dosage groups, a total of three groups. Experiments were carried out to determine the inhibitory effect of scutellarin on the growth of transplanted tumor cells in mice.

[0039] 1×105 B16 melanoma cells were planted subcutaneously in each mouse. On the second day after tumor cell transplantation, 5 mg / kg was used as the low dosage group, and 15 mg / kg was used as the high dosage group, and scutellarin dissolved in tetraethylene glycol was injected into the abdominal cavity of the animals. Inject once every other day, and stop administration after 15 consecutive days of administration. On the 28th day after the start of administration, the mice were sacrificed, the tumor mass was peeled off, and the tumor growth inhibition rate was calculate...

Embodiment 3

[0042] Example 3 Animal experiment of scutellarin on the growth inhibitory effect of transplanted tumor cells in mice

[0043] About 20 grams of C57 purebred mice 10 as a group, divided into a control group, a group of high and low dosage groups, a total of three groups. Experiments were conducted to determine the inhibitory effect of scutellarin on the growth of transplanted tumor cells in mice.

[0044] 1 × 10 cells were implanted subcutaneously in each mouse 5 B16 melanoma cells. On the second day after tumor cell transplantation, 10 mg / kg was used as the low dose group, and 30 mg / kg was used as the high dose group, and scutellarin dissolved in tetraethylene glycol was injected into the abdominal cavity of the animal. Inject once every other day, and stop administration after 15 consecutive days of administration. On the 28th day after the start of administration, the mice were sacrificed, the tumor mass was peeled off, and the tumor growth inhibition rate was calculated...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An application of wild-scutelloside and wild-scutellaglucone in preparing the antineoplastic medicines is disclosed.

Description

technical field [0001] The invention relates to a pharmaceutical use of flavonoids, in particular to the use of scutellarin and scutellarin in preparing antitumor drugs. Background technique [0002] Both scutellarin and scutellarin belong to flavonoids, which can be extracted from plants such as Scutellaria barbata. Wherein scutellarein (has another name called scutellarein, English name Scutellarein) molecular weight is 286, molecular formula C 15 h 10 o 6 , the structural formula is as follows: [0003] [0004] The molecular weight of baicalin is 463, molecular formula C 21 h 19 o 12 , the structural formula is: [0005] [0006] where R 1 Represents the glucuronic acid group. [0007] The pharmacological effects of scutellarin and scutellarin are not very clear. It has been reported in the literature that scutellarin has certain anti-inflammatory and antioxidant effects. [0008] So far, there is no report on the antitumor effect of scutellarin and scut...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P35/00
Inventor 吴一心
Owner 上海格鲁奥丽生物技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com